Trials / Completed
CompletedNCT02612623
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefapixant | Gefapixant tablets administered by mouth twice daily for 8 weeks |
| DRUG | Placebo (for gefapixant) | Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks |
Timeline
- Start date
- 2015-12-17
- Primary completion
- 2016-05-04
- Completion
- 2016-05-18
- First posted
- 2015-11-24
- Last updated
- 2019-11-25
- Results posted
- 2019-11-25
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02612623. Inclusion in this directory is not an endorsement.